Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
Glenwood Goss(Ottawa Hospital), Chun‐Ming Tsai(Taipei Veterans General Hospital), Frances A. Shepherd(Princess Margaret Cancer Centre), Lyudmila Bazhenova(Moores Cancer Center), Jong Seok Lee(Seoul National University Bundang Hospital), Gee‐Chen Chang(National Yang Ming Chiao Tung University), Lucio Crinò(University of Perugia), Miyako Satouchi(Hyogo Prefectural Cancer Center), Quincy S. Chu(University of Alberta), Toyoaki Hida(Aichi Cancer Center), Ji‐Youn Han(National Cancer Center), Óscar Juan(Hospital Universitari i Politècnic La Fe), Frank Dunphy(Duke Medical Center), Makoto Nishio(Japanese Foundation For Cancer Research), Jin‐Hyoung Kang(Catholic University of Korea), Margarita Majem(Hospital de Sant Pau), Helen Mann(AstraZeneca (United Kingdom)), Mireille Cantarini(AstraZeneca (United Kingdom)), Serban Ghiorghiu(AstraZeneca (United Kingdom)), Tetsuya Mitsudomi(Kindai University)
Cited by 641
Abstract
Related Papers
No related papers found
Powered by citation graph analysis